Safety and rapid response of dabrafenib and trametinib therapy during hyperbilirubinemia in metastatic melanoma

Walid Shalata; Rachel Steckbeck; Ilya Polishchuk; Ahron Yehonatan Cohen; Keren Rouvinov; Margarita Tokar; Ashraf Abu Jama; Omar Abu Saleh; Kim Sheva; Alexander Yakobson

doi:10.3389/fonc.2023.1102330

Safety and rapid response of dabrafenib and trametinib therapy during hyperbilirubinemia in metastatic melanoma

Walid Shalata, Rachel Steckbeck, Ilya Polishchuk, Ahron Yehonatan Cohen, Keren Rouvinov, Margarita Tokar, Ashraf Abu Jama, Omar Abu Saleh, Kim Sheva, Alexander Yakobson

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

This case report describes the occurrence of hyperbilirubinemia as a complication of metastatic melanoma. A 72-year-old male patient was diagnosed with BRAF V600E-mutated melanoma with metastases in the liver, lymph nodes, lungs, pancreas, and stomach. Due to a lack of clinical data and specific guidelines for the treatment of mutated metastatic melanoma patients with hyperbilirubinemia, a conference of specialists debated between initiating treatment or providing supportive care. Ultimately, the patient was started on the combination therapy of dabrafenib and trametinib. This treatment resulted in a significant therapeutic response via normalization of bilirubin levels and an impressive radiological response of metastases just one month post-treatment initiation.

Original language	English
Article number	1102330
Journal	Frontiers in Oncology
Volume	13
DOIs	https://doi.org/10.3389/fonc.2023.1102330
State	Published - 1 Jan 2023

Keywords

BRAF mutation (V600E)
dabrafenib
hyperbilirubinemia
metastatic melanoma
safety
trametinib

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3389/fonc.2023.1102330

Cite this

@article{09db239dea8849bdafc11bc8e272d41b,

title = "Safety and rapid response of dabrafenib and trametinib therapy during hyperbilirubinemia in metastatic melanoma",

abstract = "This case report describes the occurrence of hyperbilirubinemia as a complication of metastatic melanoma. A 72-year-old male patient was diagnosed with BRAF V600E-mutated melanoma with metastases in the liver, lymph nodes, lungs, pancreas, and stomach. Due to a lack of clinical data and specific guidelines for the treatment of mutated metastatic melanoma patients with hyperbilirubinemia, a conference of specialists debated between initiating treatment or providing supportive care. Ultimately, the patient was started on the combination therapy of dabrafenib and trametinib. This treatment resulted in a significant therapeutic response via normalization of bilirubin levels and an impressive radiological response of metastases just one month post-treatment initiation.",

keywords = "BRAF mutation (V600E), dabrafenib, hyperbilirubinemia, metastatic melanoma, safety, trametinib",

author = "Walid Shalata and Rachel Steckbeck and Ilya Polishchuk and Cohen, {Ahron Yehonatan} and Keren Rouvinov and Margarita Tokar and {Abu Jama}, Ashraf and {Abu Saleh}, Omar and Kim Sheva and Alexander Yakobson",

note = "Publisher Copyright: Copyright {\textcopyright} 2023 Shalata, Steckbeck, Polishchuk, Cohen, Rouvinov, Tokar, Abu Jama, Abu Saleh, Sheva and Yakobson.",

year = "2023",

month = jan,

day = "1",

doi = "10.3389/fonc.2023.1102330",

language = "English",

volume = "13",

journal = "Frontiers in Oncology",

issn = "2234-943X",

publisher = "Frontiers Media SA",

}

TY - JOUR

T1 - Safety and rapid response of dabrafenib and trametinib therapy during hyperbilirubinemia in metastatic melanoma

AU - Shalata, Walid

AU - Steckbeck, Rachel

AU - Polishchuk, Ilya

AU - Cohen, Ahron Yehonatan

AU - Rouvinov, Keren

AU - Tokar, Margarita

AU - Abu Jama, Ashraf

AU - Abu Saleh, Omar

AU - Sheva, Kim

AU - Yakobson, Alexander

PY - 2023/1/1

Y1 - 2023/1/1

N2 - This case report describes the occurrence of hyperbilirubinemia as a complication of metastatic melanoma. A 72-year-old male patient was diagnosed with BRAF V600E-mutated melanoma with metastases in the liver, lymph nodes, lungs, pancreas, and stomach. Due to a lack of clinical data and specific guidelines for the treatment of mutated metastatic melanoma patients with hyperbilirubinemia, a conference of specialists debated between initiating treatment or providing supportive care. Ultimately, the patient was started on the combination therapy of dabrafenib and trametinib. This treatment resulted in a significant therapeutic response via normalization of bilirubin levels and an impressive radiological response of metastases just one month post-treatment initiation.

AB - This case report describes the occurrence of hyperbilirubinemia as a complication of metastatic melanoma. A 72-year-old male patient was diagnosed with BRAF V600E-mutated melanoma with metastases in the liver, lymph nodes, lungs, pancreas, and stomach. Due to a lack of clinical data and specific guidelines for the treatment of mutated metastatic melanoma patients with hyperbilirubinemia, a conference of specialists debated between initiating treatment or providing supportive care. Ultimately, the patient was started on the combination therapy of dabrafenib and trametinib. This treatment resulted in a significant therapeutic response via normalization of bilirubin levels and an impressive radiological response of metastases just one month post-treatment initiation.

KW - BRAF mutation (V600E)

KW - dabrafenib

KW - hyperbilirubinemia

KW - metastatic melanoma

KW - safety

KW - trametinib

UR - http://www.scopus.com/inward/record.url?scp=85149840832&partnerID=8YFLogxK

U2 - 10.3389/fonc.2023.1102330

DO - 10.3389/fonc.2023.1102330

M3 - Article

C2 - 36865793

AN - SCOPUS:85149840832

SN - 2234-943X

VL - 13

JO - Frontiers in Oncology

JF - Frontiers in Oncology

M1 - 1102330

ER -

Safety and rapid response of dabrafenib and trametinib therapy during hyperbilirubinemia in metastatic melanoma

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this